Anne GeneviÃ¨ve Marcelin

List of Publications by Year
in descending order

375 papers	11,472 citations	28274 55 h-index	54911 84 g-index
387 all docs	387 docs citations	387 times ranked	11219 citing authors

#	Article	IF	Citations
1	Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. Journal of Experimental Medicine, 2007, 204, 2473-2485.	8.5	655
2	Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy. Clinical Infectious Diseases, 2010, 50, 773-778.	5.8	377
3	Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro. Antimicrobial Agents and Chemotherapy, 2008, 52, 1351-1358.	3.2	256
4	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	4.7	187
5	Rituximab therapy for HIV-associated Castleman disease. Blood, 2003, 102, 2786-2788.	1.4	152
6	Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. Aids, 2010, 24, 2365-2374.	2.2	152
7	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nature Communications, 2021, 12, 844.	12.8	146
8	The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. Journal of Infection, 2021, 83, e1-e3.	3.3	146
9	Tetherin Restricts Productive HIV-1 Cell-to-Cell Transmission. PLoS Pathogens, 2010, 6, e1000955.	4.7	141
10	Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 307-317.	5.6	131
11	The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Research, 2008, 37, 1193-1201.	14.5	128
12	Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. Emerging Infectious Diseases, 2020, 26, 1636-1637.	4.3	118
13	Characterization and structural analysis of HIV-1 integrase conservation. AIDS Reviews, 2009, 11, 17-29.	1.0	118
14	Low T Cell Responses to Human Herpesvirus 8 in Patients with AIDSâ€Related and Classic Kaposi Sarcoma. Journal of Infectious Diseases, 2006, 194, 1078-1088.	4.0	114
15	Prospective Study of the Effects of Antiretroviral Therapy on Kaposi Sarcomaâ€“Associated Herpesvirus Infection in Patients With and Without Kaposi Sarcoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 384-390.	2.1	105
16	Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. Journal of Medical Virology, 2004, 72, 162-165.	5.0	104
17	Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2003, 47, 594-600.	3.2	96
18	Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. Aids, 2008, 22, 1677-1679.	2.2	96

#	Article	IF	Citations
19	Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1762-e1765.	5.8	93
20	Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy. Journal of Virology, 2002, 76, 2634-2640.	3.4	91
21	Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2009, 63, 795-804.	3.0	91
22	OUTCOME OF KIDNEY TRANSPLANT RECIPIENTS WITH PREVIOUS HUMAN HERPESVIRUS-8 INFECTION1. Transplantation, 2000, 69, 1776-1779.	1.0	91
23	Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. Journal of Hepatology, 2006, 44, 62-67.	3.7	89
24	Factors Associated With Virological Failure in HIV-1â€“Infected Patients Receiving Darunavir/Ritonavir Monotherapy. Journal of Infectious Diseases, 2011, 204, 1211-1216.	4.0	85
25	Circulating Interleukin-6 Levels Correlate with Residual HIV Viraemia and Markers of Immune Dysfunction in Treatment-Controlled HIV-Infected Patients. Antiviral Therapy, 2012, 17, 915-919.	1.0	80
26	HHV-8 and multiple myeloma in France. Lancet, The, 1997, 350, 1144.	13.7	79
27	Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002â€“2011 survey. Aids, 2012, 26, 971-975.	2.2	77
28	Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo. Antimicrobial Agents and Chemotherapy, 2010, 54, 491-501.	3.2	74
29	Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. Aids, 2017, 31, 1048-1051.	2.2	74
30	In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2â€“Spike RBD Interface. International Journal of Molecular Sciences, 2021, 22, 1695.	4.1	72
31	Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. MBio, 2017, 8, .	4.1	71
32	High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica, 2004, 89, 1100-8.	3.5	71
33	Bone mineral density and inflammatory and bone biomarkers after darunavirâ€“ritonavir combined with either raltegravir or tenofovirâ€“emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV,the, 2015, 2, e464-e473.	4.7	69
34	Relationship between the Quantity of Kaposi Sarcomaâ€“Associated Herpesvirus (KSHV) in Peripheral Blood and Effusion Fluid Samples and KSHVâ€Associated Disease. Journal of Infectious Diseases, 2007, 196, 1163-1166.	4.0	68
35	Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resistance Updates, 2010, 13, 139-150.	14.4	68
36	Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. Journal of Antimicrobial Chemotherapy, 2015, 70, 3080-3086.	3.0	68

#	Article	IF	Citations
37	Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. Journal of Antimicrobial Chemotherapy, 2011, 66, 709-712.	3.0	67
38	Clinical Features and Contribution of Virological Findings to the Management of Kaposi Sarcoma in Organ-Allograft Recipients. Archives of Dermatology, 2000, 136, 1452-8.	1.4	66
39	Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine. Antimicrobial Agents and Chemotherapy, 2002, 46, 1586-1588.	3.2	66
40	Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transplantation, 2004, 10, 295-300.	2.4	65
41	The Impact of Preexisting or Acquired Kaposi Sarcoma Herpesvirus Infection in Kidney Transplant Recipients on Morbidity and Survival. American Journal of Transplantation, 2009, 9, 2580-2586.	4.7	65
42	Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study. Antimicrobial Agents and Chemotherapy, 2010, 54, 3335-3340.	3.2	65
43	Determinants of a Low CD4/CD8 Ratio in HIV-1â€“Infected Individuals Despite Long-term Viral Suppression. Clinical Infectious Diseases, 2016, 62, 1297-1303.	5.8	64
44	GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy*. HIV Medicine, 2004, 5, 352-359.	2.2	63
45	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. Journal of Antimicrobial Chemotherapy, 2010, 65, 2620-2627.	3.0	62
46	Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. Journal of Antimicrobial Chemotherapy, 2012, 67, 691-695.	3.0	61
47	Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 753-756.	3.0	61
48	Efficacy of protease inhibitor monotherapy vs. triple therapy: metaâ€analysis of data from 2303 patients in 13 randomized trials. HIV Medicine, 2016, 17, 358-367.	2.2	61
49	Clinically Relevant Genotype Interpretation of Resistance to Didanosine. Antimicrobial Agents and Chemotherapy, 2005, 49, 1739-1744.	3.2	60
50	Kaposi's sarcoma in HIV-negative men having sex with men. Aids, 2008, 22, 1163-1168.	2.2	59
51	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA. Aids, 2016, 30, 221-230.	2.2	59
52	Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. Aids, 2006, 20, 35-40.	2.2	57
53	Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. Journal of Antimicrobial Chemotherapy, 2010, 65, 2305-2318.	3.0	57
54	Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients. Clinical Infectious Diseases, 2022, 74, 1093-1096.	5.8	57

#	Article	IF	Citations
55	Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 24-31.	1.9	57
56	Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. Aids, 2005, 19, 25-33.	2.2	56
57	Persistence of Multidrug-Resistant HIV-1 without Antiretroviral Treatment 2 Years after Sexual Transmission. Antiviral Therapy, 2004, 9, 415-421.	1.0	56
58	Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir. Antimicrobial Agents and Chemotherapy, 2008, 52, 491-496.	3.2	54
59	Didanosine in HIVâ€1â€“Infected Patients Experiencing Failure of Antiretroviral Therapy: A Randomized Placeboâ€Controlled Trial. Journal of Infectious Diseases, 2005, 191, 840-847.	4.0	53
60	Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. Journal of Medical Virology, 2006, 78, 153-160.	5.0	53
61	Human Herpesvirus 8 (HHV8) Transmission and Related Morbidity in Organ Recipients. American Journal of Transplantation, 2013, 13, 207-213.	4.7	53
62	Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. Aids, 2010, 24, 2313-2321.	2.2	53
63	Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2005, 49, 1720-1726.	3.2	52
64	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1507-1512.	3.0	52
65	Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infectious Diseases, 2014, 14, 122.	2.9	51
66	TLR-2 Recognizes Propionibacterium acnes CAMP Factor 1 from Highly Inflammatory Strains. PLoS ONE, 2016, 11, e0167237.	2.5	51
67	Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. Journal of Infection, 2007, 54, 367-374.	3.3	50
68	New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. Journal of Antimicrobial Chemotherapy, 2014, 69, 2118-2122.	3.0	50
69	Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. Journal of Antimicrobial Chemotherapy, 2020, 75, 170-182.	3.0	50
70	Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. Journal of Antimicrobial Chemotherapy, 2010, 65, 118-124.	3.0	49
71	Soluble biomarkers of immune activation and inflammation in <scp>HIV</scp> infection: impact of 2 years of effective firstâ€line combination antiretroviral therapy. HIV Medicine, 2015, 16, 553-562.	2.2	49
72	Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2004, 48, 4687-4692.	3.2	48

#	Article	IF	Citations
73	Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial. Clinical Infectious Diseases, 2019, 69, 207-214.	5.8	48
74	Prevalence of HIV-1 Drug Resistance in Treated Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 12-18.	2.1	48
75	Distinct cytokine profiles associated with COVID-19 severity and mortality. Journal of Allergy and Clinical Immunology, 2021, 147, 2098-2107.	2.9	47
76	Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. European Respiratory Journal, 2005, 26, 969-972.	6.7	46
77	Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism. Antimicrobial Agents and Chemotherapy, 2011, 55, 2831-2836.	3.2	46
78	Bridging Î²â€Cyclodextrin Prevents Selfâ€Inclusion, Promotes Supramolecular Polymerization, and Promotes Cooperative Interaction with Nucleic Acids. Angewandte Chemie - International Edition, 2018, 57, 7753-7758.	13.8	46
79	Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19. International Journal of Infectious Diseases, 2021, 102, 10-13.	3.3	46
80	HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. Aids, 2002, 16, 2419-2424.	2.2	45
81	Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2008, 52, 3237-3243.	3.2	45
82	Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. Journal of Antimicrobial Chemotherapy, 2016, 71, 2646-2650.	3.0	45
83	Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-NaÌˆve Patients Infected with Non-B HIV-1 Subtypes. Antimicrobial Agents and Chemotherapy, 2010, 54, 728-733.	3.2	44
84	HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. Journal of Antimicrobial Chemotherapy, 2012, 67, 2323-2326.	3.0	44
85	Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8â€“specific CD8+ T cells. Blood, 2008, 111, 1387-1395.	1.4	43
86	Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. Aids, 2011, 25, 341-344.	2.2	43
87	The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. Journal of Antimicrobial Chemotherapy, 2011, 66, 2827-2830.	3.0	43
88	Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. Journal of Antimicrobial Chemotherapy, 2013, 68, 1237-1242.	3.0	42
89	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007â€“12: impact on susceptibility to first-line strategies. Journal of Antimicrobial Chemotherapy, 2015, 70, 2084-2089.	3.0	42
90	Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation. Journal of Medical Virology, 2006, 78, 877-882.	5.0	41

#	Article	IF	Citations
91	Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. Aids, 2010, 24, 614-617.	2.2	41
92	E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. Aids, 2012, 26, 1619-1624.	2.2	41
93	National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. Journal of Antimicrobial Chemotherapy, 2013, 68, 2626-2631.	3.0	41
94	Neutrophilâ€“Platelet and Monocyteâ€“Platelet Aggregates in COVID-19 Patients. Thrombosis and Haemostasis, 2020, 120, 1733-1735.	3.4	41
95	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. Aids, 2011, 25, 27-36.	2.2	40
96	Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. Journal of Antimicrobial Chemotherapy, 2018, 73, 1039-1044.	3.0	40
97	Dolutegravir resistance mutations: lessons from monotherapy studies. Current Opinion in Infectious Diseases, 2018, 31, 237-245.	3.1	39
98	Quantification of Kaposi's Sarcoma-Associated Herpesvirus in Blood, Oral Mucosa, and Saliva in Patients with Kaposi's Sarcoma. AIDS Research and Human Retroviruses, 2004, 20, 704-708.	1.1	38
99	Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. Aids, 2004, 18, 1340-1342.	2.2	38
100	Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. Journal of Antimicrobial Chemotherapy, 2009, 63, 585-592.	3.0	38
101	Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital. Clinical Infectious Diseases, 2021, 73, e4064-e4072.	5.8	38
102	Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antiviral Therapy, 2009, 14, 123-129.	1.0	38
103	Presence of HIV-1 R5 Viruses in Cerebrospinal Fluid Even in Patients Harboring R5X4/X4 Viruses in Plasma. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 60-64.	2.1	37
104	Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. Journal of Antimicrobial Chemotherapy, 2008, 62, 456-463.	3.0	36
105	Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. Journal of Antimicrobial Chemotherapy, 2010, 65, 749-751.	3.0	36
106	Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2007, 51, 3067-3074.	3.2	34
107	Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 72-77.	3.2	33
108	Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. Journal of Antimicrobial Chemotherapy, 2012, 67, 2943-2948.	3.0	33

#	Article	IF	Citations
109	Pulmonary manifestations of human herpesvirus-8 during HIV infection. European Respiratory Journal, 2013, 42, 1105-1118.	6.7	33
110	Prevalence of Human Herpesvirus 8 Infection Measured by Antibodies to a Latent Nuclear Antigen in Patients With Various Dermatologic Diseases. Archives of Dermatology, 1998, 134, 700-2.	1.4	32
111	HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. Fertility and Sterility, 2010, 93, 1020-1023.	1.0	32
112	Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study). Antimicrobial Agents and Chemotherapy, 2011, 55, 3018-3021.	3.2	32
113	Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health, 2015, 15, 209.	2.9	32
114	HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. Aids, 2005, 19, 1065-1069.	2.2	31
115	Impact of Discrepancies between the Abbott RealTime and Cobas TaqMan Assays for Quantification of Human Immunodeficiency Virus Type 1 Group M Non-B Subtypes. Journal of Clinical Microbiology, 2009, 47, 1543-1545.	3.9	31
116	Kaposi's sarcoma herpesvirus and HIV-1 seroprevalences in prostitutes in Djibouti. Journal of Medical Virology, 2002, 68, 164-167.	5.0	30
117	HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. Aids, 2010, 24, 2412-2414.	2.2	30
118	Human herpesvirus 8 infection, Castleman's disease and POEMS syndrome. British Journal of Haematology, 1999, 104, 932-933.	2.5	29
119	Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. Aids, 2005, 19, 1239-1240.	2.2	29
120	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. Journal of Antimicrobial Chemotherapy, 2013, 68, 1400-1405.	3.0	29
121	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1648-1652.	3.0	29
122	Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 433-438.	1.3	29
123	Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 1588-1590.	3.0	29
124	Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. Journal of Infection, 2022, 85, e104-e108.	3.3	29
125	Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI â€“ANRS136 Trial over 96 Weeks. PLoS ONE, 2012, 7, e41390.	2.5	28
126	Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. AIDS Research and Human Retroviruses, 2017, 33, 1-10.	1.1	28

#	Article	IF	Citations
127	Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial. Antiviral Therapy, 2002, 7, 211-218.	1.0	28
128	Kaposi's Sarcoma Associated with Previous Human Herpesvirus 8 Infection in Heart Transplant Recipients. Journal of Clinical Microbiology, 2002, 40, 2217-2219.	3.9	27
129	Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS) Tj ETQq1 1 0.784314 rgBT /Ov	5.78	27
130	HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. Aids, 2007, 21, 2243-2245.	2.2	27
131	Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. Aids, 2016, 30, 327-330.	2.2	27
132	Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. Journal of Clinical Virology, 2017, 96, 49-53.	3.1	27
133	Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective. Antiviral Therapy, 2018, 23, 463-465.	1.0	27
134	Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. Aids, 2006, 20, 287-289.	2.2	26
135	G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 739-749.	3.0	26
136	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. Journal of Antimicrobial Chemotherapy, 2019, 74, 2742-2751.	3.0	26
137	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmunity Reviews, 2021, 20, 102729.	5.8	26
138	Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies. Viruses, 2022, 14, 226.	3.3	26
139	Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali. BMC Infectious Diseases, 2019, 19, 1064.	2.9	25
140	Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?. Aids, 2020, 34, 167-175.	2.2	25
141	HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. Aids, 2007, 21, 2341-2343.	2.2	24
142	Detection of human herpesviruses HHV-6, HHV-7 and HHV-8 in whole blood by real-time PCR using the new CMV, HHV-6, 7, 8 R-geneâ„¢ kit. Journal of Virological Methods, 2008, 149, 285-291.	2.1	24
143	Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. Aids, 2008, 22, 2212-2214.	2.2	24
144	Effect of antiretroviral drugs on the quality of semen. Journal of Medical Virology, 2011, 83, 1391-1394.	5.0	24

#	Article	IF	Citations
145	Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. Journal of Antimicrobial Chemotherapy, 2012, 67, 1475-1478.	3.0	24
146	Comparison of Tests and Procedures to Build Clinically Relevant Genotypic Scores: Application to the Jaguar Study. Antiviral Therapy, 2005, 10, 479-487.	1.0	24
147	Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. Journal of Antimicrobial Chemotherapy, 2009, 64, 1087-1090.	3.0	23
148	Resistance to novel drug classes. Current Opinion in HIV and AIDS, 2009, 4, 531-537.	3.8	23
149	Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy. Antimicrobial Agents and Chemotherapy, 2010, 54, 4910-4913.	3.2	23
150	High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger. Antiviral Therapy, 2011, 16, 429-433.	1.0	23
151	The future of integrase inhibitors of HIV-1. Current Opinion in Virology, 2012, 2, 580-587.	5.4	23
152	Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. Journal of Antimicrobial Chemotherapy, 2014, 69, 2412-2419.	3.0	23
153	Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments. Aids, 2014, 28, 487-491.	2.2	23
154	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 614-617.	3.0	23
155	The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. Journal of Infection, 2021, 83, 119-145.	3.3	23
156	HUMAN HERPESVIRUS-8 SEROCONVERSIONS AFTER RENAL TRANSPLANTATION1. Transplantation, 2001, 72, 1319-1320.	1.0	23
157	Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. Journal of Medical Virology, 2004, 74, 16-20.	5.0	22
158	Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naÃ¯ve and pre-treated HIV infected patients. Journal of Medical Virology, 2007, 79, 207-211.	5.0	22
159	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	3.0	22
160	High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali. Pediatric Infectious Disease Journal, 2017, 36, e258-e263.	2.0	22
161	Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification. Retrovirology, 2018, 15, 80.	2.0	22
162	Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution. Aids, 2005, 19, 630-632.	2.2	21

#	Article	IF	Citations
163	Efficacy of Interferon-Î± for the Treatment of Kaposiâ€™s Sarcoma Herpesvirus-Associated Uveitis. American Journal of Ophthalmology, 2005, 140, 746-748.	3.3	21
164	Comparison of two genotypic algorithms to determine HIVâ€1 tropism[*]. HIV Medicine, 2008, 9, 1-5.	2.2	21
165	Structural effects of amino acid variations between B and CRF02â€AG HIVâ€1 integrases. Journal of Medical Virology, 2008, 80, 754-761.	5.0	20
166	High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. Journal of Antimicrobial Chemotherapy, 2014, 69, 2531-2535.	3.0	20
167	Systematic Review to Determine the Prevalence of Transmitted Drug Resistance Mutations to Rilpivirine in HIV-Infected Treatment-Naive Persons. Antiviral Therapy, 2016, 21, 405-412.	1.0	20
168	Characterization of a Propionibacterium acnes Surface Protein as a Fibrinogen-Binding Protein. Scientific Reports, 2017, 7, 6428.	3.3	20
169	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. Journal of Antimicrobial Chemotherapy, 2020, 75, 1026-1030.	3.0	20
170	Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antiviral Therapy, 2009, 14, 123-9.	1.0	20
171	Phenotypic Heterogeneity of Fulminant COVID-19–Related Myocarditis in Adults. Journal of the American College of Cardiology, 2022, 80, 299-312.	2.8	20
172	A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. International Journal of Antimicrobial Agents, 2013, 42, 42-47.	2.5	19
173	Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 2141-2146.	3.0	19
174	Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. Journal of Antimicrobial Chemotherapy, 2018, 73, 2485-2492.	3.0	19
175	Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2. Journal of Clinical Virology, 2020, 130, 104573.	3.1	19
176	Absence of a link between human herpesvirus 8 and pemphigus. British Journal of Dermatology, 1999, 141, 159-160.	1.5	18
177	Prevalences of herpesviruses DNA sequences in salivary gland biopsies from primary and secondary SjÃ¶gren's syndrome using degenerated consensus PCR primers. Journal of Clinical Virology, 2003, 28, 165-168.	3.1	18
178	Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. Aids, 2007, 21, 871-873.	2.2	18
179	Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 1481-1483.	3.0	18
180	Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 1470-1474.	3.0	18

#	Article	IF	Citations
181	Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B. Journal of Antimicrobial Chemotherapy, 2013, 68, 1243-1245.	3.0	18
182	Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 1086-1089.	3.0	18
183	Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing: TableÂ1.. Journal of Antimicrobial Chemotherapy, 2015, 70, 1503-1506.	3.0	18
184	Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. Journal of Medical Virology, 2005, 76, 297-301.	5.0	17
185	Stability of HIV RNA in plasma specimens stored at different temperatures. HIV Medicine, 2008, 9, 790-793.	2.2	17
186	Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. Journal of Antimicrobial Chemotherapy, 2008, 62, 905-908.	3.0	17
187	HIVâ€1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations. Journal of Molecular Recognition, 2009, 22, 480-494.	2.1	17
188	Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 2870-2880.	3.0	17
189	Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. Journal of Antimicrobial Chemotherapy, 2016, 71, 2248-2251.	3.0	17
190	Recurrence and Occurrence of Kaposiâ€™s Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. Clinical Infectious Diseases, 2020, 70, 2435-2438.	5.8	17
191	Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals. Antiviral Therapy, 2003, 8, 603-609.	1.0	17
192	Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy. Antimicrobial Agents and Chemotherapy, 2004, 48, 644-647.	3.2	16
193	HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication. Antimicrobial Agents and Chemotherapy, 2013, 57, 930-935.	3.2	16
194	Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. Journal of the International AIDS Society, 2014, 17, 19788.	3.0	16
195	Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice. Journal of Antimicrobial Chemotherapy, 2015, 70, 2347-2353.	3.0	16
196	Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw537.	3.0	16
197	iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease. Blood, 2017, 129, 855-865.	1.4	16
198	M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 1290-1293.	3.0	16

#	Article	IF	Citations
199	Prevalence of cervical HPV infection, sexually transmitted infections and associated antimicrobial resistance in women attending cervical cancer screening in Mali. International Journal of Infectious Diseases, 2021, 108, 610-616.	3.3	16
200	Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs. Journal of Clinical Microbiology, 2003, 41, 2713-2715.	3.9	15
201	Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. Aids, 2009, 23, 95-99.	2.2	15
202	Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. Scandinavian Journal of Infectious Diseases, 2010, 42, 527-532.	1.5	15
203	A Single Amino-Acid Change in a Highly Conserved Motif of gp41 Elicits HIV-1 Neutralization and Protects Against CD4 Depletion. Clinical Infectious Diseases, 2013, 57, 745-755.	5.8	15
204	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clinical Infectious Diseases, 2018, 66, 1588-1594.	5.8	15
205	Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. Journal of Antimicrobial Chemotherapy, 2019, 74, 473-479.	3.0	15
206	Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antiviral Therapy, 2007, 12, 123-9.	1.0	15
207	Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Journal of Infection, 2022, 84, e101-e104.	3.3	15
208	Phenotypic Susceptibility to Didanosine Is Associated with Antiviral Activity in Treatmentâ€Experienced Patients with HIVâ€1 Infection. Journal of Infectious Diseases, 2007, 195, 392-398.	4.0	14
209	Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy. Antimicrobial Agents and Chemotherapy, 2008, 52, 1542-1544.	3.2	14
210	Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. Journal of Antimicrobial Chemotherapy, 2008, 61, 1362-1368.	3.0	14
211	Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIVâ€1 Nonâ€nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. ChemMedChem, 2011, 6, 2203-2213.	3.2	14
212	Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. Journal of Antimicrobial Chemotherapy, 2011, 66, 1972-1975.	3.0	14
213	Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. Journal of Antimicrobial Chemotherapy, 2013, 68, 2197-8.	3.0	14
214	Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions. British Journal of Dermatology, 2016, 175, 1251-1262.	1.5	14
215	New Kaposiâ€™s sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies. Journal of Infectious Diseases, 2020, 222, 1320-1328.	4.0	14
216	Prevalence of genotypic baseline risk factors for cabotegravirâ€Šâ€Šrilpivirine failure among ARV-naive patients. Journal of Antimicrobial Chemotherapy, 2021, 76, 2983-2987.	3.0	14

#	Article	IF	Citations
217	The involvement of HIV-1 RNAse H in resistance to nucleoside analogues. Journal of Antimicrobial Chemotherapy, 2008, 61, 973-975.	3.0	13
218	Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years. Aids, 2011, 25, 537-539.	2.2	13
219	Switching to darunavir/ritonavir 800/100â€‰mg onceâ€daily containing regimen maintains virological control in fully suppressed preâ€treated patients infected with HIVâ€1. Journal of Medical Virology, 2013, 85, 8-15.	5.0	13
220	Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 1158-1166.	3.0	13
221	No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. Journal of Antimicrobial Chemotherapy, 2018, 73, 173-176.	3.0	13
222	Variability of the HIV-1 3â€² polypurine tract (3â€²PPT) region and implication in integrase inhibitor resistance. Journal of Antimicrobial Chemotherapy, 2019, 74, 3440-3444.	3.0	13
223	Interpretation of SARS-CoV-2 replication according to RT-PCR crossing threshold value. Clinical Microbiology and Infection, 2021, 27, 1056-1057.	6.0	13
224	Clinical Validation of Saquinavir/Ritonavir Genotypic Resistance Score in Protease-Inhibitor-Experienced Patients. Antiviral Therapy, 2007, 12, 247-252.	1.0	13
225	Transmitted Antiretroviral Drug Resistance in Newly HIV-Infected and Untreated Patients in SÃ©gou and Bamako, Mali. AIDS Research and Human Retroviruses, 2013, 29, 182-186.	1.1	12
226	Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes. Journal of Antimicrobial Chemotherapy, 2015, 70, 130-135.	3.0	12
227	Brief Report: De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases. Arthritis and Rheumatology, 2017, 69, 2241-2246.	5.6	12
228	Kaposiâ€™s Sarcoma-Associated Herpesvirus, the Etiological Agent of All Epidemiological Forms of Kaposiâ€™s Sarcoma. Cancers, 2021, 13, 6208.	3.7	12
229	Multicenter assessment of HIVâ€1 RNA quantitation in semen in the CREAThE network. Journal of Medical Virology, 2012, 84, 183-187.	5.0	11
230	Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases. Journal of Clinical Microbiology, 2018, 56, .	3.9	11
231	Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 1368-1375.	3.0	11
232	Caution is needed in interpreting HIV transmission chains by ultradeep sequencing. Aids, 2019, 33, 691-699.	2.2	11
233	Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antiviral Therapy, 2002, 7, 211-8.	1.0	11
234	State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap. AIDS Reviews, 2018, 20, 27-42.	1.0	11

#	Article	IF	Citations
235	Salvage Therapy with Atazanavir/Ritonavir Combined to Tenofovir in HIV-Infected Patients with Multiple Treatment Failures: Randomized Anrs 107 Trial. Antiviral Therapy, 2006, 11, 213-222.	1.0	11
236	Lack of evidence of an association between HHV-8 and multiple myeloma. Leukemia, 1998, 12, 1840-1841.	7.2	10
237	The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient. Aids, 2007, 21, 1492-1494.	2.2	10
238	Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials. Antimicrobial Agents and Chemotherapy, 2008, 52, 4251-4257.	3.2	10
239	Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase) Tj ETQq1 1 0.784314 rgBT /Overlock 1 nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Aids, 2009, 23, 1605-1608.	2.2	10
240	Upgraded Cobas Ampliprep-Cobas TaqMan Version 2.0 HIV-1 RNA Quantification Assay versus First Version: Correction of Underestimations: Fig. 1. Journal of Clinical Microbiology, 2011, 49, 2700-2702.	3.9	10
241	Positive Impact of HIV-1gagCleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir. Antimicrobial Agents and Chemotherapy, 2011, 55, 1754-1757.	3.2	10
242	Etravirine Concentrations in the Cervicovaginal Compartment in HIV-1-Infected Women Receiving Etravirine-Containing Antiretroviral Therapy: DIVA 02 Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 4018-4020.	3.2	10
243	Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. Journal of Clinical Virology, 2012, 54, 194-196.	3.1	10
244	Risk factors for raltegravir resistance development in clinical practice. Journal of Antimicrobial Chemotherapy, 2012, 67, 2494-2500.	3.0	10
245	Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. Antimicrobial Agents and Chemotherapy, 2015, 59, 4870-4881.	3.2	10
246	Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers. Clinical Infectious Diseases, 2022, 74, 707-710.	5.8	10
247	A Polymorphism at Position 400 in the Connection Subdomain of HIV-1 Reverse Transcriptase Affects Sensitivity to NNRTIs and RNaseH Activity. PLoS ONE, 2013, 8, e74078.	2.5	10
248	Impact of HIV-1 Reverse Transcriptase Polymorphism at Codons 211 and 228 on Virological Response to Didanosine. Antiviral Therapy, 2006, 11, 693-700.	1.0	10
249	International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. Antimicrobial Agents and Chemotherapy, 2010, 54, 1520-1525.	3.2	9
250	Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients. Aids, 2010, 24, 2887-2889.	2.2	9
251	Human herpesvirus 8 transfusion transmission in Ghana, an endemic region of West Africa. Transfusion, 2012, 52, 2294-2299.	1.6	9
252	Direct Quantification of Cell-Associated HIV DNA in Isolated Rectal and Blood Memory CD4 T Cells Revealed Their Similar and Low Infection Levels in Long-Term Treated HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 255-259.	2.1	9

#	Article	IF	Citations
253	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine, 2015, 16, 297-306.	2.2	9
254	Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. PLoS ONE, 2018, 13, e0198334.	2.5	9
255	Reply to Das and Berkhout, â€œHow Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravirâ€. MBio, 2018, 9, .	4.1	9
256	Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa. Journal of Antimicrobial Chemotherapy, 2018, 73, 3143-3147.	3.0	9
257	INSTI-Based Triple Regimens in Treatment-NaÃ¯ve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels. Open Forum Infectious Diseases, 2019, 6, ofz177.	0.9	9
258	A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-NaÃ¯ve Patients Starting a First-Line HAART. PLoS ONE, 2014, 9, e105853.	2.5	9
259	Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2006, 50, 2553-2556.	3.2	8
260	HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes. Journal of Antimicrobial Chemotherapy, 2013, 68, 969-972.	3.0	8
261	Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. Journal of Antimicrobial Chemotherapy, 2015, 70, 566-572.	3.0	8
262	New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. Journal of Antimicrobial Chemotherapy, 2019, 74, 2019-2023.	3.0	8
263	HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. Journal of Antimicrobial Chemotherapy, 2019, 74, 1679-1692.	3.0	8
264	Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. International Journal of Antimicrobial Agents, 2019, 53, 80-83.	2.5	8
265	Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate as an HIV-1 replication inhibitor. RSC Medicinal Chemistry, 2020, 11, 577-582.	3.9	8
266	Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2235-2241.	2.9	8
267	Poppers, by Inducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men. Open Forum Infectious Diseases, 2021, 8, ofab166.	0.9	8
268	Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antiviral Therapy, 2005, 10, 479-87.	1.0	8
269	Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey. Aids, 2007, 21, 1365-1367.	2.2	7
270	Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen. Antiviral Therapy, 2011, 17, 119-123.	1.0	7

#	Article	IF	Citations
271	Coreceptor usage in different reservoirs. Current Opinion in HIV and AIDS, 2012, 7, 450-455.	3.8	7
272	Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study. HIV Clinical Trials, 2012, 13, 284-288.	2.0	7
273	Natural evolution of CD4+ cell count in patients with CD4 >350 or >500â€‰cells/mm³ at the time of diagnosis according to HIVâ€1 coreceptor tropism. Journal of Medical Virology, 2012, 84, 1853-1856.	5.0	7
274	Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy, 2013, 68, 2199-2204.	3.0	7
275	Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France. PLoS ONE, 2015, 10, e0145885.	2.5	7
276	Virological failure of patients on maraviroc-based antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2015, 70, 1858-64.	3.0	7
277	Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). Journal of Antimicrobial Chemotherapy, 2016, 71, 2252-2261.	3.0	7
278	Host and disease factors are associated with cognitive function in European <scp>HIV</scp>â€infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	2.2	7
279	Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING. HIV Clinical Trials, 2017, 18, 1-16.	2.0	7
280	Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. Journal of Antimicrobial Chemotherapy, 2017, 72, 2351-2354.	3.0	7
281	SARS-CoV-2 infection in patients with primary central nervous system lymphoma. Journal of Neurology, 2021, 268, 3072-3080.	3.6	7
282	HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice. PLoS ONE, 2015, 10, e0138420.	2.5	7
283	XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. Frontiers in Immunology, 2021, 12, 761250.	4.8	7
284	Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. Cells, 2022, 11, 1015.	4.1	7
285	Salivary Lactoferrin Is Recognized by the Human Herpesvirus-8. Journal of Investigative Dermatology, 2005, 124, 1249-1258.	0.7	6
286	National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. Journal of Medical Virology, 2008, 80, 762-765.	5.0	6
287	HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. Journal of Antimicrobial Chemotherapy, 2008, 62, 451-455.	3.0	6
288	Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100â€ƒmg in treatment-naÃ¯ve HIV-infected patients*. HIV Medicine, 2010, 11, 666-669.	2.2	6

#	Article	IF	Citations
289	In SilicoandIn VitroComparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors. Advances in Virology, 2012, 2012, 1-13.	1.1	6
290	E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations. Antiviral Research, 2012, 93, 167-174.	4.1	6
291	Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). Journal of Antimicrobial Chemotherapy, 2015, 70, 3339-3344.	3.0	6
292	Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtype. Journal of Clinical Virology, 2016, 76, 51-54.	3.1	6
293	Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 83-91.	1.4	6
294	Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study. Journal of Antimicrobial Chemotherapy, 2019, 74, 2716-2722.	3.0	6
295	High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. International Journal of Antimicrobial Agents, 2019, 53, 678-681.	2.5	6
296	Long-term follow-up of HIV-infected patients on dolutegravir monotherapy. Journal of Antimicrobial Chemotherapy, 2020, 75, 675-680.	3.0	6
297	No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection. Aids, 2020, 34, 1745-1753.	2.2	6
298	The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris Area. Clinical Infectious Diseases, 2020, 71, e530-e531.	5.8	6
299	Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antiviral Therapy, 2003, 8, 603-9.	1.0	6
300	Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. Antiviral Therapy, 2007, 12, 247-52.	1.0	6
301	Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4<200 Cells/Mm³) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial). Antiviral Therapy, 2003, 8, 233-237.	1.0	6
302	Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data. AIDS Research and Treatment, 2012, 2012, 1-7.	0.7	5
303	Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. Aids, 2015, 29, 853-856.	2.2	5
304	Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 2651-2653.	3.0	5
305	Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. Journal of Antimicrobial Chemotherapy, 2017, 72, 3172-3176.	3.0	5
306	Ultradeep sequencing reveals HIV-1 diversity and resistance compartmentalization during HIV-encephalopathy. Aids, 2020, 34, 1609-1614.	2.2	5

#	Article	IF	Citations
307	External Validation of Atazanavir/Ritonavir Genotypic Score in HIV-1 Protease Inhibitor-Experienced Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 127-128.	2.1	5
308	Predictors of virologic response to ritonavir-boosted protease inhibitors. AIDS Reviews, 2005, 7, 225-32.	1.0	5
309	Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma. Cancers, 2022, 14, 986.	3.7	5
310	Characterization of a Cutibacterium acnes Camp Factor 1-Related Peptide as a New TLR-2 Modulator in In Vitro and Ex Vivo Models of Inflammation. International Journal of Molecular Sciences, 2022, 23, 5065.	4.1	5
311	Experience of Indinavir/Ritonavir 400/100 mg Twice-Daily Highly Active Antiretroviral Therapy-Containing Regimen in HIV-1-Infected Patients in Bamako, Mali. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 477-479.	2.1	4
312	The marriage of science and optimized HIV care in resource-limited settings. Aids, 2008, 22, 2227-2230.	2.2	4
313	Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. HIV Medicine, 2009, 10, 620-626.	2.2	4
314	Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. Journal of Antimicrobial Chemotherapy, 2012, 67, 2487-2493.	3.0	4
315	Pitfalls of HIV genotypic tropism testing after treatment interruption. Journal of Antimicrobial Chemotherapy, 2013, 68, 188-189.	3.0	4
316	Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B. Journal of Antimicrobial Chemotherapy, 2013, 68, 2515-2520.	3.0	4
317	Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. Clinical Infectious Diseases, 2018, 67, 1883-1889.	5.8	4
318	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS â€163 ETRAL Study. Pharmacotherapy, 2019, 39, 514-520.	2.6	4
319	Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. Journal of Antimicrobial Chemotherapy, 2021, 76, 2400-2406.	3.0	4
320	Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients. Journal of Infectious Diseases, 2022, 225, 502-509.	4.0	4
321	Seroprevalence and molecular diversity of Human Herpesvirus 8 among people living with HIV in Brazzaville, Congo. Scientific Reports, 2021, 11, 17442.	3.3	4
322	Primary infection with human herpesvirus 8 in an HIV-1-infected patient. Aids, 2000, 14, 1471-1473.	2.2	4
323	New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. Eurosurveillance, 2019, 24, .	7.0	4
324	Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. Diagnostics, 2022, 12, 104.	2.6	4

#	Article	IF	Citations
325	Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine. Antiviral Therapy, 2006, 11, 693-9.	1.0	4
326	SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study. Viruses, 2022, 14, 1529.	3.3	4
327	Virologic Outcome After Switching From a Nucleoside Reverse Transcriptase Inhibitor to Tenofovir in Patients With Undetectable HIV-1 RNA Plasma Level. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 876-878.	2.1	3
328	Effect of lentivirus encoding HIV-1 Nef-U3 shRNA on the function of HIV-specific memory CD4+ T cells in patients with chronic HIV-1 infection. Aids, 2009, 23, 2265-2275.	2.2	3
329	Patient-Selected Treatment Partners Did Not Protect Against Drug Resistance During First-Line NNRTI-Based HAART in a Randomized Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 563-564.	2.1	3
330	Connection Domain Mutations During Antiretroviral Treatment Failure in Mali. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 293-296.	2.1	3
331	Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies. Journal of Antimicrobial Chemotherapy, 2013, 68, 2882-2889.	3.0	3
332	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. PLoS ONE, 2015, 10, e0127816.	2.5	3
333	Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study: FigureÂ1.. Journal of Antimicrobial Chemotherapy, 2015, 70, 2418-2420.	3.0	3
334	Cost-Effectiveness of Dolutegravir/Abacavir/Lamivudine in Hiv-1 Treatment Naive Patients in France. Value in Health, 2015, 18, A587.	0.3	3
335	Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw571.	3.0	3
336	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of <scp>HIV</scp>â€1 reverse transcriptase (M184L and M184T). Chemical Biology and Drug Design, 2019, 93, 50-59.	3.2	3
337	Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali. AIDS Research and Human Retroviruses, 2019, 35, 145-149.	1.1	3
338	Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure. International Journal of Antimicrobial Agents, 2020, 56, 106039.	2.5	3
339	Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir. Journal of Antimicrobial Chemotherapy, 2021, 76, 2148-2152.	3.0	3
340	Relationship between Kaposi's sarcoma, Kaposi's sarcoma-associated herpesvirus and AIDS dementia complex. Aids, 2000, 14, 333-335.	2.2	3
341	Scoring Methods for Building Genotypic Scores: An Application to Didanosine Resistance in a Large Derivation Set. PLoS ONE, 2013, 8, e59014.	2.5	3
342	Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. Journal of Antimicrobial Chemotherapy, 2014, 69, 3356-3359.	3.0	2

#	Article	IF	Citations
343	The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. Journal of Infection, 2014, 69, 408-410.	3.3	2
344	Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. AIDS Research and Human Retroviruses, 2015, 31, 475-478.	1.1	2
345	Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e43-e45.	2.1	2
346	HIV-1 diagnosis with unquantifiable viraemia: donâ€™t be naive, look for antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 2017, 72, 630-632.	3.0	2
347	Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS) Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.0	2
348	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL studyâ€"authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2020, 75, 3699-3700.	3.0	2
349	Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali. Journal of Antimicrobial Chemotherapy, 2020, 75, 1272-1279.	3.0	2
350	Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection. Frontiers in Immunology, 2022, 13, 844727.	4.8	2
351	Human retrovirus-5 and SjÃ¶gren's syndrome. Clinical Microbiology and Infection, 1999, 5, 105-106.	6.0	1
352	Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score. Infection, 2014, 42, 295-301.	4.7	1
353	NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment. Journal of Global Antimicrobial Resistance, 2014, 2, 103-106.	2.2	1
354	Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Â32 heterozygote HIV-1-infected patient was not associated with functional cure. Journal of Antimicrobial Chemotherapy, 2015, 70, 317-319.	3.0	1
355	Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 448-454.	2.1	1
356	Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	3.0	1
357	Methods comparison for molecular diagnosis of human herpesvirus 8 infections. Journal of Clinical Virology, 2020, 126, 104308.	3.1	1
358	No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments. Journal of Antimicrobial Chemotherapy, 2021, 76, 1553-1557.	3.0	1
359	Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2021, 76, 1893-1897.	3.0	1
360	Description of the L76V Resistance Protease Mutation in HIV-1 B and â€œNon-Bâ€•Subtypes. PLoS ONE, 2013, 8, e54381.	2.5	1

#	Article	IF	Citations
361	Primaquine as a Candidate for HHV-8-Associated Primary Effusion Lymphoma and Kaposiâ€™s Sarcoma Treatment. Cancers, 2022, 14, 543.	3.7	1
362	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. Archives of Cardiovascular Diseases, 2022, 115, 96-96.	1.6	1
363	A New Topical Candidate in Acne Treatment: Characterization of the Meclozine Hydrochloride as an Anti-Inflammatory Compound from In Vitro to a Preliminary Clinical Study. Biomedicines, 2022, 10, 931.	3.2	1
364	Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e15-e17.	2.1	0
365	Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment. Journal of the International AIDS Society, 2014, 17, 19744.	3.0	0
366	Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation. Journal of Antimicrobial Chemotherapy, 2015, 70, 1919-1920.	3.0	0
367	Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men. International Journal of Antimicrobial Agents, 2019, 54, 513-517.	2.5	0
368	Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. Journal of Antimicrobial Chemotherapy, 2021, 76, 477-481.	3.0	0
369	Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours. Journal of Global Antimicrobial Resistance, 2021, 24, 311-315.	2.2	0
370	27372 Meclozine, a novel anti-inflammatory therapeutic in C acnesâ€“induced inflammation in vitro and in vivo. Journal of the American Academy of Dermatology, 2021, 85, AB138.	1.2	0
371	Inflammation and microbial translocation in treatment-controlled HIV patients. Antiviral Therapy, 2013, 18, 837-840.	1.0	0
372	HIV Coreceptor Tropism in Different Reservoirs. , 2015, , 1-4.		0
373	HIV Coreceptor Tropism in Different Reservoirs. , 2018, , 702-705.		0
374	Human Herpesvirus 8 seroprevalence among blood donors in Mali. Journal of Medical Virology, 2022, , .	5.0	0
375	More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 0, , .	3.0	0